The JV was set up in 2001 and has become increasingly peripheral to Hutchmed's core business of developing novel therapies ...

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's ...

In a statement, Neumora revealed that the KOASTAL-1 study missed its primary endpoint, with navacaprant failing to achieve a ...

The start-up – founded by investment group Flagship Pioneering – said that OPL-0401 did not meet either the primary or ...

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early ...

But with cancer remaining as one of the most prevalent and deadly forms of disease worldwide, there are a staggering number ...